HOME >> MEDICINE >> NEWS
Estrogen has antitumor activity in hormone therapy-resistant breast tumors

A pair of studies in the November 5 issue of the Journal of the National Cancer Institute suggest that low levels of estrogen--the same hormone that promotes breast cancer in its early stages--can shrink breast tumors that have developed resistance to the drugs tamoxifen and raloxifene.

Tamoxifen is a selective estrogen receptor modulator (SERM) used to treat estrogen receptor-positive breast cancers and prevent recurrence of the disease. However, tamoxifen often loses effectiveness over time and can subsequently stimulate breast cancer growth. New endocrine therapies, such as aromatase inhibitors and the antiestrogen fulvestrant, are being are used to augment the effects of tamoxifen, although some studies are suggesting that low levels of estrogen may also inhibit the growth of tamoxifen-stimulated breast tumors.

Clodia Osipo, Ph.D., and V. Craig Jordan, Ph.D., D.Sc., of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago, and their colleagues examined the effect of tamoxifen, the estrogen estradiol, and fulvestrant, both alone and in various combinations, in a mouse model of tamoxifen-stimulated human breast cancer.

The researchers found that low levels of estradiol caused tamoxifen-resistant breast tumors to regress, apparently by increasing apoptosis (cell suicide) through decreased expression of Her2/neu and NF-κB, two factors that inhibit apoptosis, and increased expression of the death receptor protein Fas, which regulates apoptosis.

Combined treatment with fulvestrant plus estradiol unexpectedly promoted the growth of tamoxifen-stimulated breast tumors, suggesting that the use of fulvestrant in patients with sufficient levels of circulating estrogen may actually stimulate tumor growth.

In the second study, Hong Liu, M.D., Ph.D., of the Robert H. Lurie Comprehensive Cancer Center, Jordan, and their colleagues examined whether low doses of estradiol would also have an
'"/>

Contact: Linda Wang
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
31-Dec-2000


Page: 1 2

Related medicine news :

1. Estrogen-associated COX-2 pathways explain protection from heart disease in female mice
2. Estrogen or stimulating environment boost memory
3. Estrogenlike drugs may eventually help postmenopausal women with weight gain
4. Estrogen offers no overall benefit for disease prevention in postmenopausal women with hysterectomy
5. Estrogen makes the brain more vulnerable to stress
6. Estrogen replacement increases risk factors for arrhythmia and sudden death
7. Estrogen may lower womens risk of heart disease by working as damper on inflammation
8. Estrogen may dictate what problem-solving strategy brain uses
9. Testosterone may reduce risk of stroke in men; Estrogen levels not related to stroke
10. Estrogens role in preventing female cardiac disease
11. Estrogen shows potential as stroke treatment, UF animal studies show

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
Breaking Medicine Technology:
Cached News: